Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getinge ABCHIX:GETIBS 73 ROC (Joel Greenblatt) % is 85.52% as of Jun. 2026, which is 74% above its 10-year median of 49.25. GuruFocus rates CHIX:GETIBS with a GF Score™ of 73/100 and a GF Value™ of kr192.70 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 837 Medical Devices & Instruments companies, Getinge AB ranks better than 94.27% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Getinge AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 85.52%.
The historical rank and industry rank for Getinge AB's ROC (Joel Greenblatt) % or its related term are showing as below:
CHIX:GETIBs'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2.5 Med: 49.25 Max: 80.07
Current: 73.14
During the past 13 years, Getinge AB's highest ROC (Joel Greenblatt) % was 80.07%. The lowest was -2.50%. And the median was 49.25%.
CHIX:GETIBs's ROC (Joel Greenblatt) % is ranked better than 94.27% of 837
companies
in the Medical Devices & Instruments industry
Industry Median: 4.35
vs CHIX:GETIBs: 73.14
Getinge AB's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -6.30% per year.
Getinge AB (CHIX:GETIBs) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Getinge AB ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Getinge AB's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:GETIBS vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Getinge AB's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getinge AB ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getinge AB's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Getinge AB's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 85.52% mean?
Getinge AB (CHIX:GETIBS) has a ROC (Joel Greenblatt) % of 85.52% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Getinge AB and its competitors. This is 74% above median its historical median of 49.25. According to the industry distribution chart, Getinge AB ranks #48 out of 837 companies in the Medical Devices & Instruments industry, placing it in the top 5.7%.
Is Getinge AB's ROC (Joel Greenblatt) % too high?
Getinge AB's current ROC (Joel Greenblatt) % of 85.52% is 74% above median its 10-year median of 49.25. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.35. Getinge AB's value of 85.52% is 1866% above this industry median. Based on the distribution chart, Getinge AB ranks #48 out of 837 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Getinge AB has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getinge AB's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getinge AB ranks #48 out of 837 companies for ROC (Joel Greenblatt) %. This places Getinge AB in the top 6% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.35. Getinge AB's value of 85.52% is 1866% above this benchmark. While the company's 10-year median is 49.25 vs. the industry median of 4.35, Getinge AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.35, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Getinge AB's current ROC (Joel Greenblatt) % of 85.52% is 1866% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Getinge AB and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getinge AB's current ROC (Joel Greenblatt) % is 85.52%, which is 74% above median its own 10-year median of 49.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getinge AB stock overvalued right now?
Based on GuruFocus' analysis, Getinge AB (CHIX:GETIBS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr192.70, compared to a current price of kr231.00 — trading 19.9% above its estimated fair value. The current ROC (Joel Greenblatt) % is 85.52%, which is 74% above median its 10-year median of 49.25 and 1866% above the Medical Devices & Instruments industry median of 4.35. Getinge AB's overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Getinge AB (CHIX:GETIBS), the current ROC (Joel Greenblatt) % is 85.52% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getinge AB (CHIX:GETIBS) Overvalued in 2026?
Based on GuruFocus' analysis, Getinge AB stock appears to be overvalued.
The current stock price of kr231.00 is trading 19.9% above its estimated GF Value™ of kr192.70.
GuruFocus considers Getinge AB to be Modestly Overvalued.
Key valuation signals for CHIX:GETIBS:
ROC (Joel Greenblatt) %: 85.52% (74% above median its 10-year median of 49.25)
GF Value™: kr192.70 vs. price of kr231.00 (19.9% above fair value)
Industry Position: 1866% above the Medical Devices & Instruments median (#48 of 837)
No single metric tells the full story. See the CHIX:GETIBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (52% of revenue), surgical workflows (35%), and life sciences (13%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales, Europe, Middle East, and Africa 35%, and Asia-Pacific the remaining 25%.
73GF Score
Get the complete analysis for CHIX:GETIBS
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GETIBS has been successfully added to your 
